Aptevo Therapeutics Inc. (APVO) stock
APVONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.59−0.07 (-10.00%)
Close on Nov 13, 2026Market cap $1.07MP/E –Yield –
Aptevo Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Aptevo Therapeutics's profit margin for the twelve months ending Dec 31, 2022 was 257.8%. For fiscal 2022 it was 257.8%, against -231.5% the year before. The highest annual figure on record is 257.8% in fiscal 2022.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 257.8% | +489.3 |
| FY2021 | Dec 31, 2021 | -231.5% | +180.4 |
| FY2020 | Dec 31, 2020 | -411.9% | −287.2 |
| FY2019 | Dec 31, 2019 | -124.7% | +108.0 |
| FY2018 | Dec 31, 2018 | -232.8% | −280.3 |
| FY2017 | Dec 31, 2017 | 47.6% | +1173.4 |
| FY2016 | Dec 31, 2016 | -1125.8% | −949.3 |
| FY2015 | Dec 31, 2015 | -176.5% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2022 | Mar 31, 2022 | -247.2% | +52.5 |
| Q4 FY2021 | Dec 31, 2021 | -171.1% | +126.1 |
| Q3 FY2021 | Sep 30, 2021 | -226.0% | +238.2 |
| Q2 FY2021 | Jun 30, 2021 | -255.0% | +1183.2 |
| Q1 FY2021 | Mar 31, 2021 | -299.7% | −209.2 |
| Q4 FY2020 | Dec 31, 2020 | -297.2% | −220.4 |
| Q3 FY2020 | Sep 30, 2020 | -464.2% | −283.0 |
| Q2 FY2020 | Jun 30, 2020 | -1438.3% | −1267.1 |
| Q4 FY2019 | Dec 31, 2019 | -90.5% | +132.1 |
| Q3 FY2019 | Sep 30, 2019 | -76.8% | +138.9 |
| Q2 FY2019 | Jun 30, 2019 | -181.1% | +11.4 |
| Q1 FY2019 | Mar 31, 2019 | -171.1% | +169.2 |
| Q4 FY2018 | Dec 31, 2018 | -222.6% | +123.7 |
| Q3 FY2018 | Sep 30, 2018 | -215.7% | −829.2 |
| Q2 FY2018 | Jun 30, 2018 | -192.6% | +124.8 |
| Q1 FY2018 | Mar 31, 2018 | -340.3% | +124.0 |
| Q4 FY2017 | Dec 31, 2017 | -346.3% | −175.9 |
| Q3 FY2017 | Sep 30, 2017 | 613.5% | +3161.1 |
| Q2 FY2017 | Jun 30, 2017 | -317.3% | – |
| Q1 FY2017 | Mar 31, 2017 | -464.3% | – |
| Q4 FY2016 | Dec 31, 2016 | -170.4% | – |
| Q3 FY2016 | Sep 30, 2016 | -2547.6% | – |
See a number that looks wrong?